Stock Ratings / Health Care / LCTX / financials

FATE (40) IPSC (28) CABA (42) OCGN (35) ⌘ Pro Terminal →

Lineage Cell Therapeutics Inc. (LCTX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$1.03 -0.96% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.03

Lineage Cell Therapeutics Inc. (LCTX) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $260.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.03 (-0.36%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LCTX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (29/100 Composite)

🔍 WHY LCTX SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+10/20 pts (34% of score)

FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 50.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (31% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.99-1% Next Q

Q2 (-2Q)

Grade E$0.98+2% Next Q

Q3 (-1Q)

Grade E$1.00+3% Next Q

Current

Grade E$1.03-9.8% Hist 90D α

Trajectory: E (21) → E (29)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LCTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LCTX currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.02) and Max Pain ($1.08) forces dealer call-delta covering toward $2.19.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LCTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LCTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 29%NO 71%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How LCTX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $8.9M

FY24

Rev $9.5M

FY25

Rev $14.6M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$14.6M	52%	-80%	-$63.5M	-$19.4M	-45%
FY 2024	$9.5M	96.5%	-80%	-$18.6M	-$23.7M	-45%
FY 2023	$8.9M	52%	-80%	-$21.5M	-$28.6M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LCTX)

✓Walkthrough of LCTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LCTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -31.79%📐 HORIZONTAL RANGE

2026-10-30O $1.04H $1.05L $0.98C $1.03VOL 1.17M

RES: $1.41SUP: $0.76SMA50: $1.02SMA200: $1.33

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LCTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LCTX Butterfly Map → + Track LCTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LCTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LCTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LCTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LCTX)

Health Care Rank #954 of 1016 ⚔️ FATE vs LCTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LCTX vs. FATE, IPSC, CABA, OCGN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lineage Cell Therapeutics Inc. (LCTX) ranks #954 by composite RQD confidence (29/100, grade E) and #541 by equity capitalization ($260.5M). Within this direct 5-issuer industry benchmark cohort, LCTX leads on earnings valuation at N/A trailing P/E, while IPSC leads on capital efficiency and profitability with -14.1% ROIC and — gross margin. CABA currently holds the highest overall quantitative score in the immediate peer group at 42/100 (D-) compared with LCTX at 29/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LCTX ACTIVE Lineage Cell Therapeutics Inc.	E	29/100	—	—	-35.0%	-0.96%	$260.5M	Benchmark Subject
FATE Fate Therapeutics Inc.	D-	40/100	—	—	-35.0%	0.00%	$260.0M	/fate-vs-lctx →
IPSC Century Therapeutics Inc.	E	28/100	—	—	-14.1%	-2.67%	$264.4M	/ipsc-vs-lctx →
CABA Cabaletta Bio Inc.	D-	42/100	—	—	-35.0%	+4.28%	$268.7M	/caba-vs-lctx →
OCGN Ocugen Inc.	D-	35/100	—	—	-35.0%	-4.15%	$252.4M	/ocgn-vs-lctx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000876343

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lineage Cell Therapeutics Inc. (LCTX) reported GAAP revenue of $14.6M (+53.2% vs. FY2024 revenue of $9.5M , and +62.7% cumulative change since FY2023) , GAAP net income of -$63.5M, operating cash flow of -$18.9M, and free cash flow of -$19.4M (+17.8% YoY). On the balance sheet, LCTX closed FY2025 with $112.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$14.6M	-$63.5M	-$18.9M	-$19.4M	$112.6M	—
FY2024 (FY)	2024-12-31	$9.5M	-$18.6M	-$23.1M	-$23.7M	$113.2M	—
FY2023 (FY)	2023-12-31	$8.9M	-$21.5M	-$28.6M	-$28.6M	—	—

3. LCTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LCTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Lineage Cell Therapeutics Inc. (NYSE: LCTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.03 (-0.96% 1D, market cap $260.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LCTX ranks #954 in composite RQD confidence.

How does LCTX compare to FATE and IPSC in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LCTX carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FATE (Fate Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $260.0M) and IPSC (Century Therapeutics Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC -14.1%, cap $264.4M). Among the 5-stock peer group, LCTX leads on earnings multiple (N/A) while IPSC leads on capital efficiency (-14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LCTX?

Per LCTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000876343), Lineage Cell Therapeutics Inc. generated $14.6M in revenue (+53.2% YoY), -$63.5M in net income, and -$19.4M in free cash flow against $112.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LCTX trading relative to its 50-day, 200-day, and 52-week technical levels?

LCTX last traded at $1.03 (-0.96% on volume of 937,738 shares), positioning the stock +0.98% above its 50-day simple moving average ($1.02) and -22.56% below its 200-day simple moving average ($1.33). Across its 52-week range of $0.88 to $2.09, LCTX sits at the 12.4% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.16).